<DOC>
	<DOCNO>NCT02277613</DOCNO>
	<brief_summary>This double-blind , sham-controlled clinical study evaluate safety feasibility AMI MultiStem therapy subject heart attack ( Non-ST elevation MI ) .</brief_summary>
	<brief_title>A Phase 2 Trial AMI MultiStem® Therapy Subjects With Non-ST Elevation Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Subjects either gender , 1885 year age , inclusive Diagnosis nonST elevation myocardial infarction ( NSTEMI ) Left Ventricular Ejection Fraction ( LVEF ) ≥ 25 ≤ 45 % Previous Coronary Artery Bypass Graft ( CABG ) Previous autologous , allogeneic bone marrow peripheral stem cell transplant Previous solid organ transplant Anticipated need additional plan coronary revascularization procedure ( ) Hemodynamic instability Mechanical complication index acute myocardial infarction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>stem cell</keyword>
</DOC>